

Preparing Europe for Novel Psychedelic-Assisted Therapies

The launch meeting of PAREA (virtual)

23rd June; 14:00 – 16:00 CEST

AGENDA

- 14:00** **Welcome**
Prof. David Nutt, PAREA Chair
- 14:07** **Opening keynote address**
*Dr Thomas R. Insel, Former Director of the US National Institute of Mental Health (2002 – 2015)**
- 14:17** **Opening remarks from the EU policy maker**
*Dr Sara Cerdas, Member of the European Parliament**
- 14:21** **Testimonial from participant of psychedelic-assisted therapy**
Awakn Life Sciences case study
*Dave Pounds, Phase IIa trial participant – MDMA for Alcohol Use Disorder**
- 14:30** **Psychedelic medicines + Audience Q&A**
Prof. Gitte Moos Knudsen, University of Copenhagen and President of the European College of Neuropsychopharmacology
- 14:55** **PAREA: The Time is Now**
Tadeusz Hawrot: PAREA Founder and Policy Lead
- 15:10** **In discussion with the EU and PAREA members + Audience Q&A**
Panel moderated by Frederic Destrebecq, PAREA Vice Chair and European Brain Council Executive Director, with:
European Medicines Agency: Dr Florence Butlen-Ducuing - Senior Scientific Officer, Office of Therapies for Neurological and Psychiatric Disorders
European Commission: Dr Tim Raemaekers, Policy and Programme Officer, Combatting Diseases Unit, DG Research
PAREA members perspectives:
Patients: Jacinta Hastings, Global Alliance of Mental Illness Advocacy Networks – GAMIAN Europe
Artemis Komatina, Association of European Cancer Leagues Patient Support Working Group, Cyprus Association of Cancer Patients and Friends
Psychedelic foundation: Joost Breeksema, Executive Director, Open Foundation
Industry: Dr. Amir Inamdar, Chief Medical Officer, Cybin
- 15:50** **Closing remarks and launch of a Call to Action**
Deirdre Ryan, PAREA Vice Chair and Pain Alliance Europe President

* These sections of the agenda re pre-recorded